Terms: = Germ cell tumor AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Diagnosis
586 results:
1. In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma.
Murphy C; Devis-Jauregui L; Struck R; Boloix A; Gallagher C; Gavin C; Cottone F; Fernandez AS; Madden S; Roma J; Segura MF; Piskareva O
PLoS One; 2024; 19(5):e0303643. PubMed ID: 38809883
[TBL] [Abstract] [Full Text] [Related]
2. Retinoblastoma - A comprehensive review, update and recent advances.
Nag A; Khetan V
Indian J Ophthalmol; 2024 Jun; 72(6):778-788. PubMed ID: 38804799
[TBL] [Abstract] [Full Text] [Related]
3. A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework.
Hussein R; Abou-Shanab AM; Badr E
NPJ Syst Biol Appl; 2024 May; 10(1):52. PubMed ID: 38760476
[TBL] [Abstract] [Full Text] [Related]
4. Development and validation of a novel nomogram for predicting overall survival patients with neuroblastoma.
Zhao JD; Lu XY; Chen TP; Duan XL; Zuo W; Sai K; Zhu LR; Gao Q
Eur J Surg Oncol; 2024 Jun; 50(6):108321. PubMed ID: 38598875
[TBL] [Abstract] [Full Text] [Related]
5. mycn immunohistochemistry as surrogate marker for mycn-amplified spinal ependymomas.
Mohan D; Nambirajan A; Malik R; Sharma A; Suri V; Kaur K; Doddamani R; Garg A; Gupta S; Mallick S; Sharma MC
Hum Cell; 2024 May; 37(3):704-713. PubMed ID: 38411836
[TBL] [Abstract] [Full Text] [Related]
6. Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations.
Amano H; Uchida H; Harada K; Narita A; Fumino S; Yamada Y; Kumano S; Abe M; Ishigaki T; Sakairi M; Shirota C; Tainaka T; Sumida W; Yokota K; Makita S; Karakawa S; Mitani Y; Matsumoto S; Tomioka Y; Muramatsu H; Nishio N; Osawa T; Taguri M; Koh K; Tajiri T; Kato M; Matsumoto K; Takahashi Y; Hinoki A
Cancer Sci; 2024 May; 115(5):1634-1645. PubMed ID: 38411285
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
8. Pediatric spinal ependymoma with chromothripsis of chromosome 6: a case report and review of the literature.
Scott KR; Gener MA; Repnikova EA
J Med Case Rep; 2024 Feb; 18(1):95. PubMed ID: 38351155
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play.
Satgunaseelan L; Sy J; Shivalingam B; Sim HW; Alexander KL; Buckland ME
Pathology; 2024 Mar; 56(2):158-169. PubMed ID: 38233331
[TBL] [Abstract] [Full Text] [Related]
11. Treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
13. Pediatric neuroblastoma with intraspinal extension: the role of surgical management.
Chang D; Oh T; Roland JL; Matthay KK; Vo KT; Edwards CS; Sun PP; Auguste KI; Gupta N
J Neurosurg Pediatr; 2024 Mar; 33(3):245-255. PubMed ID: 38100763
[TBL] [Abstract] [Full Text] [Related]
14. Neuroblastoma Patients' Outcome and Chromosomal Instability.
Ognibene M; De Marco P; Amoroso L; Fragola M; Zara F; Parodi S; Pezzolo A
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958497
[TBL] [Abstract] [Full Text] [Related]
15. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.
Wang H; Wang X; Xu L
Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225
[TBL] [Abstract] [Full Text] [Related]
16. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to
Batra V; Gikandi A; Pawel B; Martinez D; Granger MM; Marachelian A; Park JR; Maris JM; Vo KT; Matthay KK; DuBois SG
Pediatr Blood Cancer; 2024 Jan; 71(1):e30743. PubMed ID: 37885116
[TBL] [Abstract] [Full Text] [Related]
17. Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting MYC-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation.
Jiang P; Zhang T; Wu B; Li X; Fu M; Xu B
Med Oncol; 2023 Oct; 40(11):332. PubMed ID: 37843625
[TBL] [Abstract] [Full Text] [Related]
18. A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study.
Li M; Duan X; Li C; You D; Liu L
Medicine (Baltimore); 2023 Sep; 102(38):e34925. PubMed ID: 37746942
[TBL] [Abstract] [Full Text] [Related]
19. The evolution of spinal cord surgery: history, people, instruments, and results.
Shimony N; Fehnel K; Abbott IR; Jallo GI
Childs Nerv Syst; 2023 Oct; 39(10):2687-2700. PubMed ID: 37658937
[TBL] [Abstract] [Full Text] [Related]
20. Stage 4N neuroblastoma before and during the era of anti-G
Kushner BH; LaQuaglia MP; Cardenas FI; Basu EM; Gerstle JT; Kramer K; Roberts SS; Wolden SL; Cheung NV; Modak S
Int J Cancer; 2023 Dec; 153(12):2019-2031. PubMed ID: 37602920
[TBL] [Abstract] [Full Text] [Related]
[Next]
